Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board
Onco-Innovations (OTCQB:ONNVF) has appointed Dr. Michael Lock, Professor in Oncology and Medical Biophysics at the University of Western Ontario, to its Scientific and Clinical Advisory Board. Dr. Lock brings extensive experience in clinical trial design, translational oncology, and multidisciplinary cancer care.
Dr. Lock's distinguished career includes leadership roles as Chair of Radiation Oncology, Chief of Division of Radiation Oncology, and Medical Director of the London Regional Cancer Program. His international contributions include work with the IAEA, UN, and WHO. The appointment aims to support Onco's development of novel therapies, particularly its PNKP inhibitor program.
Additionally, the company's Board has approved a grant of 1,155,000 Restricted Share Units to directors, officers, and consultants.
Onco-Innovations (OTCQB:ONNVF) ha nominato il Dott. Michael Lock, Professore di Oncologia e Biophysics Medica presso l'Università di Western Ontario, al suo Consiglio Scientifico e Clinico Consultivo. Il Dott. Lock porta una vasta esperienza nella progettazione di trial clinici, nell'oncologia translazionale e nell'assistenza oncologica multidisciplinare.
La carriera del Dott. Lock è caratterizzata da ruoli di leadership quali Presidente di Radioterapia Oncologica, Capo della Divisione di Radioterapia e Direttore Medico del London Regional Cancer Program. Il suo contributo internazionale comprende collaborazioni con IAEA, ONU e OMS. L'obiettivo di questa nomina è sostenere lo sviluppo di nuove terapie da parte di Onco, in particolare il suo programma inibitore di PNKP.
Inoltre, il Consiglio ha approvato una erogazione di 1.155.000 Restricted Share Units per dirigenti, dirigenti e consulenti.
Onco-Innovations (OTCQB:ONNVF) ha designado al Dr. Michael Lock, Profesor de Oncología y Biofísica Médica en la Universidad de Western Ontario, para su Consejo Asesor Científico y Clínico. El Dr. Lock aporta una amplia experiencia en diseño de ensayos clínicos, oncología translacional y atención oncológica multidisciplinaria.
La distinguida trayectoria del Dr. Lock incluye cargos de liderazgo como Presidente de Oncología Radioterápica, Jefe de la División de Radioterapia y Director Médico del London Regional Cancer Program. Sus aportes internacionales incluyen trabajo con la IAEA, la ONU y la OMS. La designación busca apoyar el desarrollo de nuevas terapias de Onco, en particular su programa de inhibidor de PNKP.
Además, la Junta de la compañía ha aprobado una asignación de 1,155,000 Restricted Share Units para directores, ejecutivos y asesores.
Onco-Innovations (OTCQB:ONNVF)가 University of Western Ontario의 종양학 및 의학 생물물리학 교수인 Dr. Michael Lock를 과학 및 임상 자문위원회에 임명했습니다. Dr. Lock은 임상시험 설계, 종양 전환의학 및 다학제적 암 치료 분야에서 풍부한 경력을 보유하고 있습니다.
Dr. Lock의 화려한 경력에는 방사선 종양학 의장, 방사선 종양학과장, London Regional Cancer Program의 의료 이사가 포함됩니다. 국제적 기여로는 IAEA, UN, WHO와의 협력이 있습니다. 이번 임명의 목적은 Onco의 신약 개발을 지원하는 것으로, 특히 PNKP 억제제 프로그램에 중점을 두고 있습니다.
또한 회사의 이사회는 이사, 임원, 컨설턴트에게 1,155,000 Restricted Share Units를 부여하는 승인을 받았습니다.
Onco-Innovations (OTCQB:ONNVF) a nommé le Dr Michael Lock, Professeur en Oncologie et Bio-physique Médicale à l’Université de Western Ontario, au sein de son Conseil Scientifique et Clinique Consultatif. Le Dr Lock apporte une vaste expérience en conception d’essais cliniques, en oncologie translationnelle et en soins oncologiques multidisciplinaires.
La carrière distinguée du Dr Lock comprend des postes de direction tels que Président de l’Oncologie Radiologique, Chef de la Division d’Oncologie Radiologique et Directeur Médical du London Regional Cancer Program. Ses contributions internationales incluent des collaborations avec l’AIEA, l’ONU et l’OMS. Cette nomination vise à soutenir le développement de nouvelles thérapies par Onco, en particulier son programme inhibiteur de PNKP.
Par ailleurs, le Conseil d’administration a approuvé l’allocation de 1 155 000 Restricted Share Units destinées aux administrateurs, cadres et consultants.
Onco-Innovations (OTCQB:ONNVF) hat Dr. Michael Lock, Professor für Onkologie und medizinische Biophysik an der University of Western Ontario, in seinen Wissenschaftlichen und Klinischen Beirat berufen. Dr. Lock bringt umfangreiche Erfahrungen in der Gestaltung klinischer Studien, translationaler Onkologie und interdisziplinärer Krebsversorgung mit.
Dr. Locks herausragende Laufbahn umfasst Führungsfunktionen wie Vorsitzender der Strahlentherapie, Leiter der Abteilung Strahlentherapie und Medizinischer Direktor des London Regional Cancer Program. Zu seinen internationalen Beiträgen gehören Arbeiten mit der IAEA, UNO und WHO. Die Ernennung soll Oncos Entwicklung neuartiger Therapien unterstützen, insbesondere sein PNKP-Hemmstoffprogramm.
Zudem hat der Vorstand des Unternehmens die Gewährung von 1.155.000 Restricted Share Units an Direktoren, Vorständen und Beratern genehmigt.
Onco-Innovations (OTCQB:ONNVF) عيّنت الدكتور مايكل لوك، أستاذ في علم الأورام والفيزياء الحيوية الطبية في جامعة ويسترن أونتاريو، في مجلسها الاستشاري العلمي والسريري. يجلب الدكتور لوك خبرة واسعة في تصميم التجارب السريرية، وعلم الأورام الانتقالي، ورعاية السرطان متعددة التخصصات.
تشمل مسيرته المهنية المميزة أدوار قيادية مثل رئيس قسم العلاج الإشعاعي، ورئيس قسم العلاج الإشعاعي، ومدير الطبي لبرنامج لندن الإقليمي للسرطان. وتشمل مساهماته الدولية عمله مع الوكالة الدولية للطاقة الذرية، والأمم المتحدة، ومنظمة الصحة العالمية. يهدف التعيين إلى دعم تطوير علاجات جديدة لـ Onco، ولا سيما برنامج مثبط PNKP.
إلى جانب ذلك، وافق مجلس إدارة الشركة على منح 1,155,000 وحدة أسهم مقيدة للمخرجين التنفيذيين والمديرين والمستشارين.
Onco-Innovations (OTCQB:ONNVF) 已任命 迈克尔·洛克博士，加拿大西安大略大学肿瘤学与医学生物物理学教授，加入其科学与临床咨询委员会。洛克博士在临床试验设计、翻译性肿瘤学以及多学科癌症护理方面具有丰富经验。
洛克博士的杰出职业生涯包括担任放射肿瘤学主席、放射肿瘤科主任以及伦敦区域癌症计划的医疗主任等领导职务。他在国际层面的贡献包括与IAEA、联合国和世界卫生组织的工作。此次任命旨在支持Onco开发新疗法，特别是其PNKP抑制剂计划。
此外，公司董事会已批准向董事、高级职员与顾问授予 1,155,000份受限股单位。
- Appointment of highly qualified Dr. Lock with extensive clinical trial and oncology expertise
- Strategic addition to support development of PNKP inhibitor program
- Access to international healthcare networks through Dr. Lock's WHO, UN, and IAEA connections
- Issuance of 1,155,000 RSUs may lead to potential dilution for existing shareholders
VANCOUVER, BC / ACCESS Newswire / September 22, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce the appointment of Dr. Michael Lock, Professor in the Department of Oncology and the Department of Medical Biophysics at the University of Western Ontario, to its Scientific and Clinical Advisory Board. Dr. Lock's expertise in clinical trial design, translational oncology, and multidisciplinary cancer care will support Onco in its development of novel therapies, including its PNKP inhibitor program.
Dr. Lock is a Professor at Western University in the Department of Oncology and the Department of Medical Biophysics. He is a staff radiation oncologist who trained at Princess Margaret Hospital, University of Toronto, McMaster University, and the University of Wisconsin. Over his career, he has held leadership roles as Chair of the Department of Radiation Oncology, Chief of Division of Radiation Oncology, Medical Director of the London Regional Cancer Program, and Southwest Regional Radiation Oncology Lead. His experience spans clinical operations, trial oversight, and strategic program development across multiple oncology subspecialties.
He has chaired and co-chaired several multidisciplinary site teams, including Breast Cancer, Genitourinary, and Hepatobiliary programs, ensuring integration of clinical research into patient care. Dr. Lock also served as Chair of the Radiation Oncology Provincial Advisory Committee, where he helped shape provincial priorities that established protocols and infrastructure that will serve patients for many years to come. He is an Associate Scientist with the Lawson Health Research Institute. His leadership in clinical trial methodology, coupled with his ability to align diverse research teams, will be highly relevant to Onco's translational and clinical pipeline.
In addition to his work in Canada, Dr. Lock has contributed to advancing cancer care globally through collaborations with the International Atomic Energy Agency (IAEA), the United Nations (UN), and the World Health Organization (WHO).[1] He has received multiple recognitions, including the Human Touch Award and the MAC Administrative Award, for his leadership and contributions to oncology.
"Dr. Lock's deep clinical trial expertise and proven leadership in integrating research with patient care make him an invaluable addition to our team. His perspective will be critical as Onco advances toward clinical development of our PNKP inhibitor program and other research initiatives, particularly in shaping trial strategy and execution," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
The Company also announces that its Board of Directors has approved a grant of 1,155,000 Restricted Share Units ("RSUs") to certain directors, officers, and consultants of the Company pursuant to the Company's equity incentive plan.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated closing date, use of proceeds and anticipated proceeds thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
[1] https://www.lhsc.on.ca/verspeeten-family-cancer-centre/michael-lock-md-ccfp-frcpc
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
Who is Dr. Michael Lock and why did Onco-Innovations (ONNVF) appoint him?
What experience does Dr. Lock bring to Onco-Innovations (ONNVF)?
How will Dr. Lock's appointment benefit Onco-Innovations' PNKP inhibitor program?
How many Restricted Share Units (RSUs) did Onco-Innovations grant in September 2025?
